Ligand price target raised to $160 from $150 at Barclays

Barclays raised the firm’s price target on Ligand (LGND) to $160 from $150 and keeps an Overweight rating on the shares. The company’s above-consensus 2025 guidance includes 30% year-over-year royalty revenue 9% adjusted earnings growth at the midpoint, the analyst tells investors in a research note. The firm views Ligand’s five-year updated outlook as compelling.